CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 2, 2011, Pages 205-211

  Palmeira, Carlos ^a   Lameiras, Catarina ^b   Amaro, Teresina ^b   Lima, Luís ^b   Koch, Alberto ^b   Lopes, Carlos ^c   Oliveira, Paula A ^d   Santos, Lúcio ^a  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Bladder cancer; CIS; DNA content; Genetic instability; Ki 67 immunoexpression; P53 immunoexpression

Indexed keywords

CELL NUCLEUS DNA; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER CELL; CARCINOGENESIS; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DNA CONTENT; FEMALE; GENE OVEREXPRESSION; GENETIC MARKER; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; INVASIVE CARCINOMA; LABELING INDEX; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; FEMALE; GENOMIC INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79952042552     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.022     Document Type: Article

References (32)

1. Pasin E., Josephson D.Y., Mitra A.P., et al. Superficial bladder cancer: An update on etiology, molecular, molecular, development, classification, and natural history. Rev Urol 2008, 10:31-43.
2. Dyrskjøt L., Kruhøffer M., Thykjaer T., et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004, 64:4040-4048.
3. Takenaka A., Yamada Y., Miyake H., et al. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol 2008, 15:309-313.
4. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
5. Jakse G., Hall R., Bono A., et al. Intravesical BCG in patients with carcinoma of the urinary bladder: Long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 2001, 40:144-150.
6. Losa A., Hurle R., Lembo A. Low dose bacillus Calmette-Guérin for carcinoma in situ of the bladder: Long-term results. J Urol 2000, 163:79-80.
7. Greene F.L., Page D.L., Fleming I.D., et al. AJCC Cancer staging manual 2002, Springer Verlag, New York (NY). 6th ed.
8. Sauter G., Algaba F., Amin M., et al. Tumors of the urinary system: Noninvasive urothelial neoplasias. WHO classification of tumors of the urinary system and male genital organs 2004, 110-123. IARCC Press, Lyon. J.N. Eble, G. Sauter, J.L. Epstein (Eds.).
9. Lopez-Beltran A., Sauter G., Gasser T., et al. Tumors of the urinary system: Infiltrating urothelial carcinoma. WHO classification of tumors of the urinary system and male genital organs 2004, 93-109. IARCC Press, Lyon. J.N. Eble, G. Sauter, J.L. Epstein (Eds.).
10. Oliveira P.A., Palmeira C., Lourenço L.M., et al. Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. J Exp Clin Cancer Res 2005, 24:609-616.
11. Santos L., Amaro T., Costa C., et al. Ki-67 Index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 2003, 105:267-272.
12. Santos L., Lameiras C., Afonso J., et al. Is DNA content alteration a consequence of proliferative and differentiation changes in urothelial bladder tumors?. Acta Urol 2003, 20:9-17.
13. Palmeira C., Oliveira P.A., Arantes-Rodrigues R., et al. DNA cytometry and kinetics of rat urothelial lesions during chemical carcinogenesis. Oncol Rep 2009, 21:247-252.
14. Oliveira P.A., Palmeira C., Colaço A., et al. DNA content analysis, expression of Ki-67, and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with mitomycin C and bacillus Calmette-Guérin. Anticancer Res 2006, 26:2995-3004.
15. Oliveira P.A., Adega F., Palmeira C.A., et al. DNA study of bladder papillary tumors chemically induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in Fisher rats. Int J Exp Pathol 2007, 88:39-46.
16. Oliveira P., Palmeira C., Colaço A., et al. Cell proliferation and DNA content in rat urothelial lesions after repeat intravesical instillations of mitomycin C and bacillus Calmette-Guérin. Urol Int 2008, 80:90-97.
17. Rosin M.P., Cairns P., Epstein J.I., et al. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995, 55:5213-5216.
18. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788.
19. Dyrskjøt L., Zieger K., Real F.X., et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 2007, 13:3545-3551.
20. Höglund M. Bladder cancer, a two phased disease?. Semin Cancer Biol 2007, 17:225-232.
21. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000, 163:1124-1129.
22. Gofrit O.N., Pode D., Pizov G., et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guérin immunotherapy. Urol Oncol 2009, 27:258-262.
23. Agarwal P.K., Kamat A.M. Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. Indian J Urol 2008, 24:77-83.
24. Bellmunt J., Albiol S., Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment, and follow-up. Ann Oncol 2008, 19:ii47-ii48.
25. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
26. Raj G.V., Herr H., Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2006, 177:1283-1286.
27. Kulkarni G.S., Finelli A., Fleshner N.E., et al. Optimal management of high-risk T1G3 bladder cancer: A decision analysis. PloS Med 2007, 4:1538-1549.
28. Huguet J., Crego M., Sabaté S., et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: Pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005, 48:53-59.
29. Gupta A., Lotan Y., Bastian P.J., et al. Bladder Cancer Research Consortium. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008, 71:302-307.
30. Denzinger S., Fritsche H.M., Otto W., et al. Early vs. deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach?. Eur Urol 2008, 53:146-152.
31. Thalmann G. Organ preservation for T1G3 bladder cancer: Is it feasible?. Eur Urol 2008, 53:27-29.
32. Solsona E., Iborra I., Rubio J., et al. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumor. BJU Int 2004, 94:1258-1262.